Candidate Biomarkers of Liver Fibrosis: A Concise, Pathophysiology-oriented Review
Open Access
- 2 July 2018
- journal article
- review article
- Published by Xia & He Publishing in Journal of Clinical and Translational Hepatology
- Vol. 6 (3), 1-9
- https://doi.org/10.14218/jcth.2018.00006
Abstract
Repair of sustained liver injury results in fibrosis (i.e. the accumulation of extracellular matrix proteins), and ultimately the complete distortion of parenchymal architecture of the liver, which we call cirrhosis. Detecting and staging of fibrosis is thus a mainstay in the management of chronic liver diseases, since many clinically relevant decisions, such as starting treatment and/or monitoring for complications including hepatocellular carcinoma, may depend on it. The gold standard for fibrosis staging is liver biopsy, the role of which, however, is questioned nowadays because of cost, hazards and poor acceptance by patients. On the other hand, imaging techniques and/or measurement of direct and indirect serum markers have not proved to be completely satisfactory under all circumstances as alternatives to liver biopsy. Making progress in this field is now more crucial than ever, since treatments for established fibrosis appear on the horizon. Fine dissection of the pathways involved in the pathophysiology of liver diseases has put forward several novel candidate biomarkers of liver fibrosis, such as growth arrest-specific6, Mac-2-binding protein, osteopontin, placental growth factor, growth/differentiation factor 15 and hepatocyte growth factor. All molecules have been suggested to have potential to complement or substitute methods currently used to stage liver diseases. Here, we review the pros and cons for their use in this setting.Keywords
This publication has 124 references indexed in Scilit:
- Cooperative Unfolding of Compact Conformations of the Intrinsically Disordered Protein OsteopontinBiochemistry, 2013
- A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitisScientific Reports, 2013
- Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin αVβ3 engagement and PI3K/pAkt/NFκB signalingJournal of Hepatology, 2011
- Growth arrest-specific protein 6 is hepatoprotective against murine ischemia/reperfusion injuryJournal of Hepatology, 2010
- The role of osteopontin in inflammatory processesJournal of Cell Communication and Signaling, 2009
- Elevated serum concentrations of activated hepatocyte growth factor activator in patients with multiple myelomaEuropean Journal of Haematology, 2008
- FibroMeters: a family of blood tests for liver fibrosisGastroentérologie Clinique et Biologique, 2008
- Fibroindex, a practical index for predicting significant fibrosis in patients with chronic hepatitis CJournal of Hepatology, 2007
- Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfectionJournal of Hepatology, 2006
- A model to predict survival in patients with end-stage liver diseaseJournal of Hepatology, 2001